S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:TNDM

Tandem Diabetes Care (TNDM) Stock Price, News & Analysis

$35.41
+0.11 (+0.31%)
(As of 03/28/2024 ET)
Today's Range
$35.06
$36.09
50-Day Range
$22.09
$35.41
52-Week Range
$13.82
$43.51
Volume
1.81 million shs
Average Volume
2.38 million shs
Market Capitalization
$2.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.36

Tandem Diabetes Care MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
2.7% Upside
$36.36 Price Target
Short Interest
Bearish
12.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.64
Upright™ Environmental Score
News Sentiment
1.11mentions of Tandem Diabetes Care in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.62) to ($1.07) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.78 out of 5 stars

Medical Sector

697th out of 939 stocks

Surgical & Medical Instruments Industry

73rd out of 97 stocks

TNDM stock logo

About Tandem Diabetes Care Stock (NASDAQ:TNDM)

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

TNDM Stock Price History

TNDM Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Tandem Diabetes Care (NASDAQ:TNDM) Trading Down 5%
Shhh! 7 Small-Cap Stocks That Can Double by 2025
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Parexel Announces CEO Succession Plan
TNDM Aug 2024 35.000 call
TNDM Apr 2024 30.000 call
OGI, SFIX and AVAV are among after hour movers
Why Tandem Diabetes Care Stock Popped Today
See More Headlines
Receive TNDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
3/28/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:TNDM
Fax
N/A
Employees
2,400
Year Founded
2006

Price Target and Rating

Average Stock Price Target
$36.36
High Stock Price Target
$62.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+2.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
12 Analysts

Profitability

Net Income
$-222,610,000.00
Pretax Margin
-29.46%

Debt

Sales & Book Value

Annual Sales
$747.72 million
Book Value
$4.81 per share

Miscellaneous

Free Float
63,990,000
Market Cap
$2.32 billion
Optionable
Optionable
Beta
1.08

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

TNDM Stock Analysis - Frequently Asked Questions

Should I buy or sell Tandem Diabetes Care stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TNDM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TNDM, but not buy additional shares or sell existing shares.
View TNDM analyst ratings
or view top-rated stocks.

What is Tandem Diabetes Care's stock price target for 2024?

12 equities research analysts have issued 12-month price targets for Tandem Diabetes Care's shares. Their TNDM share price targets range from $21.00 to $62.00. On average, they anticipate the company's share price to reach $36.36 in the next year. This suggests a possible upside of 2.7% from the stock's current price.
View analysts price targets for TNDM
or view top-rated stocks among Wall Street analysts.

How have TNDM shares performed in 2024?

Tandem Diabetes Care's stock was trading at $29.58 at the beginning of the year. Since then, TNDM stock has increased by 19.7% and is now trading at $35.41.
View the best growth stocks for 2024 here
.

Are investors shorting Tandem Diabetes Care?

Tandem Diabetes Care saw a increase in short interest in March. As of March 15th, there was short interest totaling 8,080,000 shares, an increase of 64.9% from the February 29th total of 4,900,000 shares. Based on an average daily volume of 1,800,000 shares, the days-to-cover ratio is currently 4.5 days.
View Tandem Diabetes Care's Short Interest
.

When is Tandem Diabetes Care's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our TNDM earnings forecast
.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) released its earnings results on Wednesday, February, 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.04. The medical device company earned $196.80 million during the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative trailing twelve-month return on equity of 31.48% and a negative net margin of 29.77%.

When did Tandem Diabetes Care's stock split?

Shares of Tandem Diabetes Care reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What guidance has Tandem Diabetes Care issued on next quarter's earnings?

Tandem Diabetes Care updated its first quarter 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $175.0 million-$175.0 million, compared to the consensus revenue estimate of $186.1 million.

What is John Sheridan's approval rating as Tandem Diabetes Care's CEO?

11 employees have rated Tandem Diabetes Care Chief Executive Officer John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Block (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.77%), Vanguard Group Inc. (10.70%), Capital World Investors (9.79%), Eminence Capital LP (7.93%), Bellevue Group AG (3.06%) and Jennison Associates LLC (1.98%). Insiders that own company stock include Brian B Hansen, Christopher J Twomey, Christopher J Twomey, David B Berger, Dick Allen, Elizabeth Anne Gasser, James Leal, John F Sheridan, Kathleen Mcgroddy-Goetz, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson, Rebecca B Robertson, Shannon Marie Hansen and Susan Morrison.
View institutional ownership trends
.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TNDM) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners